PTC Therapeutics, Inc.
PTCT
$66.71
$2.223.44%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 114.51% | 97.54% | 96.00% | 91.12% | -13.97% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 114.51% | 97.54% | 96.00% | 91.12% | -13.97% |
| Cost of Revenue | -15.14% | -16.31% | -7.16% | -10.83% | -19.15% |
| Gross Profit | 471.61% | 326.20% | 304.88% | 334.42% | 4.44% |
| SG&A Expenses | 15.36% | 14.51% | 8.14% | -3.23% | -9.51% |
| Depreciation & Amortization | -59.26% | -86.11% | -92.53% | -94.46% | -72.72% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -8.32% | -16.68% | -17.82% | -25.08% | -25.92% |
| Operating Income | 683.66% | 821.89% | 550.40% | 410.40% | 58.00% |
| Income Before Tax | 291.84% | 274.16% | 234.82% | 200.87% | 47.84% |
| Income Tax Expenses | 7,840.34% | -138.66% | 353.65% | 184.93% | 100.25% |
| Earnings from Continuing Operations | 287.90% | 265.87% | 231.21% | 202.70% | 42.02% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 287.90% | 265.87% | 231.21% | 202.70% | 42.02% |
| EBIT | 683.66% | 821.89% | 550.40% | 410.40% | 58.00% |
| EBITDA | 1,359.53% | 4,270.83% | 6,935.62% | 3,029.36% | 36.99% |
| EPS Basic | 285.92% | 261.83% | 227.01% | 198.37% | 43.52% |
| Normalized Basic EPS | 408.94% | 398.51% | 324.40% | 283.36% | 54.85% |
| EPS Diluted | 263.27% | 243.81% | 210.22% | 184.59% | 43.44% |
| Normalized Diluted EPS | 370.05% | 369.11% | 299.49% | 262.86% | 54.85% |
| Average Basic Shares Outstanding | 2.63% | 2.06% | 2.07% | 2.28% | 2.68% |
| Average Diluted Shares Outstanding | 8.13% | 7.60% | 4.79% | 5.01% | 2.68% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |